Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naive Patients in Chile
Más información
Título según WOS: | Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naive Patients in Chile |
Título según SCOPUS: | Cost effectiveness of daclatasvir/asunaprevir versus peginterferon/ribavirin and protease inhibitors for the treatment of hepatitis c genotype 1b Naïve patients in Chile |
Título de la Revista: | PloS one |
Volumen: | 10 |
Número: | 11 |
Editorial: | Public Library of Science |
Fecha de publicación: | 2015 |
Idioma: | English |
DOI: |
10.1371/journal.pone.0141660 |
Notas: | ISI, SCOPUS |